Kymera Therapeutics enters its May 7 earnings call with two forces pulling in opposite directions: short sellers have been cutting exposure for six weeks, yet options traders are more defensively positioned than they have been in months.
The short retreat is the more striking move. Short interest as a percentage of free float peaked near 19.1% in early April and has since dropped to 17.5% — a meaningful unwind of roughly 1.6 percentage points. That decline accelerated around April 23, when the position dropped by more than a full percentage point in a single session, suggesting at least some shorts covered ahead of the Q1 print. The direction of travel is clearly one of de-risking on the bearish side.
Options tell the opposite story. The put/call ratio is running at 1.44, well above its 20-day average of 1.03 and about 1.5 standard deviations elevated. The ratio has climbed steadily since mid-April, rising from the 0.70s to the 1.40s over roughly three weeks. That shift points to growing demand for downside protection heading into tomorrow's event. Borrow conditions, by contrast, remain unremarkable. Cost to borrow is 0.57% — barely above its one-month average — and availability is ample, meaning there is no squeeze pressure in the lending market even with 17.5% of float still short.
The Street is notably constructive. Canaccord Genuity initiated coverage today with a Buy rating and a $106 target — the most recent addition to a broadly bullish analyst pack. That $106 entry point sits below the mean target of around $119, which in turn implies roughly 44% upside to yesterday's close of $82.71. Other recent changes have been mostly positive in direction: UBS raised its target to $128 in early March, and Citigroup lifted to $120 at the same time. Jefferies trimmed to $110 in mid-March while maintaining its Buy — the modest cut stands out as the lone note of caution from major firms this year. The consensus is firmly in buy territory, with bulls pointing to the company's pipeline of immunology degraders and the strategic partnership infrastructure around them. Bears flag the still-long commercialisation timeline, ITK-related safety questions, and competition building in the protein degradation space.
Insider activity is worth noting, though the read is ambiguous. CEO and founder Nello Mainolfi sold approximately $2.4 million worth of stock on April 29 at prices between $80.74 and $82.45. Founder and Chairman Bruce Booth sold around $730,000 in mid-to-late April. Atlas Venture Fund also trimmed across multiple tranches. These are relatively small as a percentage of the company and carry low trade-significance scores, making them hard to interpret as anything beyond routine portfolio management — but the cluster of selling at current levels does not go unnoticed ahead of a catalyst.
On the institutional side, FMR added nearly 3 million shares in the quarter to March 31, bringing its position to 10.85% of shares outstanding — the single largest holder by some distance. Vanguard added 846,000 shares in the same period. FMR filed an updated Schedule 13G/A today, drawing attention to the position. That concentration of ownership at the top is a meaningful offset to the insider selling narrative.
The May 7 event and fresh preclinical data on KT-579, Kymera's IRF5 degrader presented at Digestive Disease Week this week, are the dual catalysts to watch. The last quarterly print on April 30 produced only a fractional negative move, while the February result was followed by a 1-day gain that reversed into a 7.9% five-day loss. The pattern is modest on the day, choppier over the week.
What to watch: whether tomorrow's call provides any update on trial timelines that shifts the bull-to-bear balance the Street currently has tilted heavily toward the buy side.
See the live data behind this article on ORTEX.
Open KYMR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
